Condition: Cervical Cancer · Sponsor: Fujian Cancer Hospital
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.
This description comes directly from the study's public registry record.
Qin Xu, Ph.D · 0591-0-62752366 · xuqin@fjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Fujian Medical University Affiliated Second Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Zhangzhou Affiliated Hospital of Fujian Medical University | Zhangzhou, Fujian, China | Recruiting |
| Zhujiang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Not Yet Recruiting |
| The Affiliated Hospital of Inner Mongolia Medical University | Hohhot, Inner Mongolia, China | Not Yet Recruiting |
| The Second Hospital of Dalian Medical University | Dalian, Liaoning, China | Not Yet Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Not Yet Recruiting |
| The Second Qilu Hospital of Shandong University | Jinan, Shandong, China | Not Yet Recruiting |
| Shandong Provincial Hospital | Jinan, Shandong, China | Not Yet Recruiting |
| Cancer Hospital of Shandong First Medical University | Jinan, Shandong, China | Not Yet Recruiting |
| Affiliated Hospital of Jining Medical University | Jining, Shandong, China | Not Yet Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07256236